posaconazole vs vorapaxar
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of posaconazole and vorapaxar. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Strong CYP3A Inhibitors Avoid concomitant use of ZONTIVITY with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ] .
Noxafil
Zontivity
Posaconazole is an antifungal medicine. It helps prevent certain fungal infections in people with weakened immune systems.
Vorapaxar (Zontivity) helps prevent blood clots if you have had a heart attack or have peripheral artery disease. It works by stopping platelets in your blood from sticking together and forming clots.
Posaconazole prevents Aspergillus and Candida infections. You may need this medicine if you have a high risk of getting these infections. This often includes people who had a stem cell transplant or have certain blood cancers and are on chemotherapy.
Vorapaxar is used to lower the chance of having serious heart problems if you have a history of heart attack or peripheral artery disease (PAD). PAD is when you have narrowed arteries that reduce blood flow to your limbs. This medicine can help prevent heart death, heart attack, stroke, and the need for urgent procedures to open blocked heart arteries.
Posaconazole belongs to a class of drugs called azole antifungals. It works by stopping the growth of fungi. This helps your body fight off the infection.
Vorapaxar is a PAR-1 antagonist, which means it blocks a specific receptor on platelets. This receptor, called protease-activated receptor-1 (PAR-1), normally causes platelets to clump together. By blocking PAR-1, vorapaxar helps prevent blood clots from forming.
- • Diarrhea
- • Nausea
- • Fever
- • Vomiting
- • Headache
- • Bleeding
- Febrile Neutropenia 1,017
- Drug Interaction 930
- Death 928
- Pyrexia 850
- Neutropenia 705
No adverse event reports.
Posaconazole can interact with many other medicines. It can cause heart rhythm problems (QT prolongation). It can also cause liver problems. Tell your doctor about all the medicines you take.
Vorapaxar can cause serious bleeding, including bleeding in the brain, which can be fatal. You should not take this medicine if you have a history of stroke, transient ischemic attack (TIA), or bleeding in the brain. Also, do not take it if you have active bleeding.
Posaconazole may harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if posaconazole passes into breast milk, so talk to your doctor if you are breastfeeding.
It is not known if vorapaxar will harm an unborn baby. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Also Compare, Nearby Drugs
Compare posaconazole with
How to Read This posaconazole vs vorapaxar Comparison
posaconazole is classified in the Azole Antifungal drug class, while vorapaxar sits within the PAR-1 Antagonist (Antiplatelet) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, posaconazole has 4,430 submissions while vorapaxar has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to posaconazole interferes with the way your body clears vorapaxar, which can lead to an unsafe buildup of the medication.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for posaconazole or vorapaxar.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.